Navigation Links
Initial Studies of Channel Medsystems' Cryothermic Therapy Demonstrate Preliminary Safety and Tolerability; Results Presented at the 42nd AAGL Global Congress
Date:11/21/2013

SAN FRANCISCO, Nov. 21, 2013 /PRNewswire/ -- Results from histopathology and initial tolerability studies of Channel Medsystems' novel technology for endometrial ablation were presented at last week's AAGL Global Congress in Washington, D.C. The findings represent a first indication of the safety and effectiveness of this device, which is intended for use in the treatment of heavy menstrual bleeding, a condition that affects one in five women in the United States.  The published data demonstrate that the Company's cryothermic therapy had preliminary safety, created a favorable ablation profile, and was well-tolerated by subjects.  Evidence from these initial studies forms the foundation of a data set designed to prove that Channel Medsystem's device is an appropriate technology for the physician office setting.

(Logo: http://photos.prnewswire.com/prnh/20131111/SF14418LOGO)

These initial studies were performed in subjects undergoing a planned hysterectomy. Histopathology data from these studies were analyzed by Dr. James Coad, a pathologist from West Virginia University and co-author of the published data.

The studies demonstrated that Channel Medsystems' cryothermic therapy (1) had an acceptable safety profile, (2) can be performed in a clinically appropriate timeframe, and (3) was well-tolerated by the subject without the need for general anesthesia or conscious sedation.  In addition, evaluation of the removed uteri revealed excellent cavity coverage and an ablation profile that mirrors currently-available hyperthermic therapies.  "This procedure appears to facilitate an appropriate depth of ablation of the endometrium, from a full-thickness ablation of the body of the uterus to a thinner ablation that is desirable in the cornua and lower uterine segment," said Dr. Coad.  "The precision in the depth of ablation is a key factor in achieving an effective outcome without compromising the function of the underlying uterine tissue."

"These results are promising and indicate that our cryothermic therapy is ready for the next stage of evaluation," said Ric Cote, President and CEO of Channel Medsystems.  "We are looking forward to beginning enrollment in our Cryoablation Feasibility Trial (CRYSTAL), where we will focus on assessing outcomes in women with heavy menstrual bleeding up to six months after the procedure."  The CRYSTAL study is designed to further evaluate the effectiveness and tolerability of Channel Medsystems' in-office cryothermic procedure at leading centers in Canada and will begin enrollment this month.

About the Cryothermic Technology Platform: Channel Medsystems' novel cryothermic technology and streamlined delivery system were developed with feedback from leading clinicians and biomedical engineers at the healthcare incubator, Theranova. The technology integrates cryothermic energy and the user controls into a self-contained, handheld device, eliminating the need for a separate control unit or capital equipment.

About Channel Medsystems:  Channel Medsystems is a venture-backed company that was founded to bring innovation to the delivery of women's healthcare. The Company strives to develop treatments to meet the unique needs of female patients and the high standards of their healthcare providers. Channel Medsystems is committed to ensuring that patients have access to high quality outcomes that can be delivered in the convenience and comfort of their healthcare provider's office. For more information, please visit www.channelmedsystems.com.

CAUTION: This device is available for investigational use in Canada.  It is not available for sale or investigational use in the United States.


'/>"/>
SOURCE Channel Medsystems
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Montage Healthcare and Mammography Reporting Systems to show initial results of partnership to enrich mammography quality efforts at RSNA 2013
2. Tandem Diabetes Care Announces Closing of Initial Public Offering
3. Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Initial Public Offering of Common Stock
4. Epizymes EPZ-5676 DOT1L Inhibitor Demonstrates Encouraging Initial Findings in an Ongoing Phase 1 Dose Escalation Study
5. Tandem Diabetes Care Prices Initial Public Offering
6. American Red Cross Contributes an Initial $6 Million to Support Typhoon Haiyan Response Efforts in Philippines
7. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
8. Veracyte, Inc. Announces Pricing of Initial Public Offering
9. Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013
10. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
11. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016 Quantum Radiology,s Mobile Breast ... radiologist interpretation directly to women at the workplace, thereby ... such as Delta Air Lines and SunTrust Bank, and ... a component of wellness initiatives. "I think ... It enables them to have a mammogram without taking ...
(Date:12/2/2016)... , Dec. 2, 2016  Eli Lilly and Company ... guidance for 2017 and provide updated financial guidance for ... conduct a conference call on that day with the ... financial guidance. The conference call will begin ... public can access a live webcast of the conference ...
(Date:12/2/2016)... , December 2, 2016 Orthopedic ... & Support) is Expected to Gain a Significant Market Share ... Orthopedic Ailments  ... , According to a ... on Medical Implants Sterile Packaging: Clamshell Product Type Segment Projected ...
Breaking Medicine Technology:
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
(Date:12/2/2016)... NJ (PRWEB) , ... December 02, 2016 , ... Sourced ... Water has some unique properties including its unmatched natural purity of just 6 ppm ... clean and crisp. , Nothing Water has been available in several ShopRite and FoodTown ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:12/2/2016)... ... 2016 , ... ‘Tis the season for giving! Today, 20 creative teams across ... Partnership and the Drug Enforcement Administration as part of the National Red Ribbon Week ... schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be ...
(Date:11/30/2016)... ... November 30, 2016 , ... Standard Process, ... an annual ranking and recognition of the largest closely held companies headquartered in ... from 2008-2016. In addition, Standard Process was awarded the Talent Award for providing ...
Breaking Medicine News(10 mins):